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Objective: Despite advances in technology, optimal glucose control remains 
elusive and neonatal complications ubiquitous in type 1 diabetes (T1D) pregnancy. 
Our aim was to examine the safety, efficacy and longer-term feasibility of day-and-
night closed-loop. 
Research Design and Methods: We recruited 16 pregnant women (mean age 32.8 
(5.0) years, T1D duration 19.4 (10.2) years, HbA1c 8.0 (1.1)%, BMI 26.6 (4.4) 
kg/m2) to an open-label, randomized, crossover trial. Participants completed 28 
days of closed-loop and sensor-augmented pump (SAP) separated by a washout. 
Afterwards, participants could continue using closed-loop up to 6-weeks post-
partum. The primary endpoint was the proportion of time with glucose levels within 
target range (63-140mg/dl).  
Results: The proportion of time with glucose levels within target was comparable 
during closed-loop and SAP (62.3% vs 60.1%; CI95% -4.1 to 8.3; p=0.47). Mean 
glucose and time spent hyperglycemic >140mg/dl also did not differ (131.4 vs 
131.4mg/dl; p=0.85 and 36.6 vs 36.1%; p=0.86). During closed-loop, there were 
fewer hypoglycemia episodes; median (range) 8 (1-17) vs 12.5 (1-53) over 28 days; 
p=0.04 and less time <63mg/dl (1.6 vs 2.7%; p=0.02). Hypoglycemia <50mg/dl 
(0.24 vs 0.47%; p=0.03) and low blood glucose index (1.0 vs 1.4; p=0.01) were 
lower. There was also less nocturnal hypoglycemia (23.00-07.00hr) during closed-
loop (1.1 vs 2.7%; p=0.008) and a trend towards higher overnight time-in-target 
(67.7 vs 60.6%; p=0.06).  
Conclusion: Closed-loop was associated with comparable glucose control and 
significantly less hypoglycemia than SAP therapy. Larger, longer duration, 
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multicenter trials are now indicated to determine clinical efficacy of closed-loop in 




Type 1 diabetes (T1D) in pregnancy is associated with increased risk of maternal and 
neonatal complications (1-3). These complications, attributed to greater fetal 
exposure to maternal hyperglycemia, occur more commonly in women with 
suboptimal glucose control (4). Thus, the primary focus of treatment in T1D 
pregnancy is to reduce fetal exposure to hyperglycemia without increasing maternal 
hypoglycemia. Recent evidence suggests that although continuous glucose 
monitoring (CGM) improves day-to-day glucose control, with approximately 1-
hour/day less hyperglycemia in women using multiple daily injections (MDI) and 
continuous subcutaneous insulin infusion (CSII), optimal maternal glycemia was not 
achieved (5). 
Thus, even with increasing use of new CGM and CSII technologies, pregnant women 
with T1D continue to spend on average eight hours each day, hyperglycemic (5, 6). 
Furthermore, two-thirds of T1D offspring have complications related to maternal 
hyperglycemia, including large for gestational age (LGA), and preterm delivery 
which contribute to high rates of neonatal intensive care unit (NICU) admissions (4, 
5). 
Hybrid closed-loop insulin delivery (artificial pancreas) systems provide automated 
glucose-responsive insulin delivery between meals and overnight, with manually 
triggered pre-meal doses (7). Closed-loop has been evaluated in children, adolescent, 
and adult populations under inpatient, outpatient, and home conditions and is 
associated with reduced exposure to hyperglycemia and hypoglycemia (8, 9). Short-
term studies including non-pregnant adults with near-optimal glucose control 
(HbA1c<7.5%) suggest potential for reduced hypoglycemia (10). A recent systematic 
review and meta-analyses including 585 participants across 27 outpatient studies 
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found consistent improvements in glucose control across a wide variety of clinical 
settings and closed-loop systems (11). 
Closed-loop may be useful in T1D pregnancy, when glucose control targets are 
tighter and the burden of hypoglycemia burden is greater (12). The physiological 
changes in insulin sensitivity and day-to-day variability in insulin pharmacokinetics 
make achieving near-optimal glycemia challenging (7, 13). Our recent trial of 
overnight closed-loop, found a 15% increased time-in-target (75 vs 60%; p=0.002) 
between 23.00-07.00hr with closed-loop compared to SAP (14, 15). However, 
achieving optimal glucose control is substantially more challenging during the 
daytime when meals, snacks and exercise require manual pre-meal boluses with or 
without basal dose adjustment (16). As hybrid closed-loop systems adjust only basal 
insulin, the potential role of day-and-night closed-loop in T1D pregnancy is 
unknown. Our aim was to evaluate the safety, efficacy and longer-term feasibility of 
day-and-night closed-loop in pregnant women with T1D.  
Methods 
Study design 
The trial was an open-label, randomized, two-period crossover study in pregnant 
women, assessing the safety, efficacy and longer-term feasibility of day-and-night 
closed-loop, as compared to SAP therapy, during T1D pregnancy.  
After providing written informed consent, participants were trained on the use of the 
study CGM (FreeStyle Navigator 2, Abbott Diabetes Care, Alameda, CA, USA) and 
pump (DANA-R, Diabecare, Sooil, Seoul, South Korea) devices and practiced using 
them for 2-4 weeks before completing a device competency assessment to document 
that participants were competent using the study CGM and pump. Participants were 
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randomized to either 4-weeks of closed-loop (intervention) or 4-weeks of real-time 
CGM and CSII without closed-loop (SAP control). At the end of the first phase there 
was a 1-2 week washout, before participants crossed to the alternate phase. After the 
randomized trial, women could choose to resume their previous intensive insulin 
therapy or continue using the study devices (any combination of CGM, pump or 
closed-loop) throughout pregnancy and delivery and for up to 6 weeks post-partum. 
As in our previous overnight closed-loop study, this pragmatic extension provided a 
longer-term feasibility assessment and minimized ethical concerns about 
discontinuing a potentially beneficial treatment during pregnancy (14). 
The randomization schedule was created with an automated web-based programme, 
using permuted four-block schedule maintained in a secure database, ensuring that 
allocation was concealed from trial staff and participants. Participants were recruited 
from three UK National Health Service (NHS) antenatal clinics (Cambridge, 
Norwich, Ipswich). Women participated from within the home and antenatal clinic 
setting, with 24-hour support provided by the research team throughout.    
Capillary glucose testing was recommended at least seven times daily with National 
Institute for Health and Clinical Excellence (NICE) glucose targets in both groups 
(pre-meal 63-99mg/dl, one-hour post meal <140mg/dl). There were no restrictions 
on exercise, meals or overseas travel and no remote monitoring. Participants had 
antenatal clinic visits every two weeks. 
HbA1c outcome measurements were taken at randomization, the end of each 
crossover period, 28, 32 and 36 weeks gestation, and six weeks after delivery. They 
were analyzed at a central laboratory (Addenbrooke’s Hospital, Cambridge, UK) 
using an International Federation of Clinical Chemistry and Laboratory Medicine 
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(IFCC) aligned method (TOSOH Bioscience G7 HPLC analyser; inter-assay CV 
3.71% at HbA1c 5.41%; 1.7% at HbA1c 10.6%). Quality and quantity of sleep was 
assessed using the Pittsburgh Sleep Quality Index (PSQI), a sleep diary and by 
actigraphy (Actiwatch, Philips Respironics)(17). Participants completed 
questionnaires (Diabetes Technology Questionnaire and Hypoglycaemia Fear 
Survey) at baseline and at the end of each crossover (18, 19). Reportable adverse 
events included all serious adverse events other than pre-specified protocol 
exceptions. 
Study participants  
We recruited pregnant women who had T1D for at least one year before pregnancy. 
Women were aged between 18-45 years and had a singleton pregnancy with 
ultrasound-confirmed gestational age between 8-24 weeks. They had had intensive 
insulin treatment (either MDI or CSII), and a booking HbA1c level of ≥6.5 and ≤10% 
(≥48 and ≤86mmol/mol). Participants were required to speak and understand English 
and have email access.   
Exclusion criteria included a physical or psychological disease likely to interfere with 
the conduct of the study, medications known to interfere with glucose metabolism, 
and insulin dose of ≥1.5 units/kg.  
Study oversight 
The study protocol was approved by the Health Research Authority, East of England 
Regional Ethics Committee (15/EE/0278), with notification of no objection provided 
by the Medicines and Healthcare Products Regulatory Agency, UK (CI/2015/0042). 
All participants provided written informed consent. Details of the protocol and pre-
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specified trial outcomes are available on the International Standard Randomised 
Controlled Trial Number register (ISRCTN 83316328). 
Closed-loop system 
The closed-loop system (Florence D2A, University of Cambridge, Cambridge, UK) 
used CGM glucose measurements to automatically adjust insulin rates. Real-time 
glucose readings were transmitted using Bluetooth via a purpose-built translator to 
an android mobile phone (Samsung Galaxy S4, Samsung, South Korea), which 
housed the algorithm. The control algorithm (University of Cambridge, version 
0.3.41p) aimed for interstitial glucose levels of 104.4-131.4mg/dl, adjusting for 
fasting and post-meal conditions and for accuracy of glucose prediction. The control 
algorithm included enhanced adaptation of insulin needs based on identification of 
the time of day, compared to that used in our previous overnight home study (14)  
and is not substantially different from the usual Cambridge algorithm used in non-
pregnant studies (10).  
It incorporated learning about day-to-day insulin doses and adapted insulin delivery 
for particular times of day when individual participant requirements were higher or 
lower. Every 12 minutes, the insulin dose was communicated via Bluetooth to the 
DANA pump, which delivered insulin. The DANA pumps were modified in-house 
(replacement caps inserted) to allow participants to select their preferred infusion set 
from a range of commercially available consumables including Medtronic 
(Northridge, California, USA) and Animas (West Chester, Pennsylvania, USA). 
Pre-meal insulin boluses were given manually, 15-30 minutes before eating, using 
the pump’s bolus calculator. To initialize closed-loop, participant’s weight and total 
daily insulin dose were entered manually, with insulin pump settings automatically 
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transferred using Bluetooth. Safety rules limited maximum insulin dose and 
suspended insulin delivery when glucose levels were falling rapidly and/or 
<77.4mg/dl. Capillary glucose calibration tests were advised twice daily (before 
breakfast and evening meal). Recalibration of CGM was recommended if sensor and 
capillary glucose levels differed by ≥54mg/dl.  
At the start of closed-loop, participants had a device training session (30-60 minutes). 
This included instructions for starting and stopping closed-loop and troubleshooting 
for technical issues. During the randomized trial and follow-up, participants were 
advised to use closed-loop continuously. To maintain device connectivity, 
participants had to be within approximately 30 meters of the devices. There were no 
changes to announce for antenatal corticosteroids, labor, or delivery but the non-
pregnant glucose targets (70-180mg/dl) were applied immediately post-partum. 
Participants had access to a 24-hour phone line staffed by the research team. 
 
Study endpoints 
Safety endpoints included nocturnal (23:00-07:00hr) and/or severe hypoglycemia 
episodes (defined as requiring third party assistance and/or capillary glucose < 
50mg/dl associated with clinical symptoms) and other adverse events.  
The primary efficacy endpoint was the percentage of time spent within the T1D 
pregnancy target range (63-140mg/dl), as measured by CGM during the 4-week 
intervention periods. Pre-specified secondary glycemic outcomes, derived from 
CGM measures, included mean glucose, time >140 and >180mg/dl (to quantify fetal 
hyperglycemic exposure), time <63 and <50mg/dl (to quantify maternal 
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hypoglycemia), maternal hypoglycemia episodes (<63mg/dl for ≥20 minutes 
duration), low blood glucose index (LBGI) to quantify hypoglycemia duration and 
extent (20), and standard deviation (SD) to quantify glucose variability. Additional 
outcomes included central laboratory HbA1c, time in non-pregnant target range (70-
180mg/dl), CGM compliance, total insulin dose, questionnaires and measures of 
sleep. 
The longer-term feasibility of day-and-night closed-loop (from the end of the 
randomized trial until delivery) was assessed by CGM measures during pre-specified 
intervals (28-32, 32-36 and from 36 weeks until delivery). The glucose target range 
was adjusted to 70-180mg/dl (non-pregnant), during the assessment period from after 
delivery until up to 6-weeks post-partum.  
Statistical analysis 
Previous study participants using SAP therapy spent 61.7 (24.9)% time-in-target 
(16, 21). To detect a 30% relative increase (from 62% to 80%), we estimated that a 
sample size of 16 participants was needed to achieve 80% power and an alpha level 
of 0.05 (two-tailed). The standard deviation of the primary outcome was assumed to 
be 25% (16, 21). 
Statistical analyses were performed on an intention-to-treat basis. A 5% 
significance level was used for all comparisons without adjustment for multiplicity. 
Outcomes were calculated with GStat version 2.2 software (University of 
Cambridge, Cambridge UK) and statistical analyses performed using SPSS and R. 
Results during the randomized crossover study phases were compared using linear 
mixed effects models, with the response variable being time-in-target; the study arm 
as a fixed effect; and study participant and 4-week block as nested random effects.  
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Role of the funding source  
The funders had no role in the trial design, data collection, data analysis, data 
interpretation, or the decision to publish. Abbott Diabetes Care (Alameda, California, 
USA) provided discounted CGM devices and consumables. The National Institute 
for Health Research and Abbott Diabetes Care reviewed the manuscript prior to 
submission but did not play a role in manuscript preparation or revision. The 
corresponding author (HRM) oversaw the conduct of the trial, had full access to all 





Nineteen participants were recruited to the study (Figure 1). Of these, two withdrew 
prior to randomization (one disliked study pump, one experienced mental health 
deterioration) and one withdrew due to pregnancy complications. This participant 
had preterm premature rupture of membranes with severe oligohydramnios during 
her first (SAP) study phase. She underwent an elective termination of pregnancy, 
and was withdrawn at 20 weeks gestation. Sixteen participants completed the 
randomized crossover trial and are included in the analyses. Their baseline 
characteristics are shown, with equal numbers of pump and MDI users and nine 
(56%) participants with suboptimal HbA1c (Table 1). 
Randomized crossover trial outcomes 
There was no difference in the primary outcome, percentage of time in the target 
glucose range (63-140mg/dl), during closed-loop and SAP (62.3% vs 60.1%; 
absolute difference 2.1%, CI95% -4.1 to 8.3; p=0.47, Table 2). Likewise, mean 
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glucose and time spent hyperglycemic >140mg/dl did not differ between closed-
loop and SAP (131.4 vs 131.4mg/dl; p=0.85 and 36.6 vs 36.1%; p=0.86). During 
the 4-weeks of closed-loop, there were fewer episodes of maternal hypoglycemia; 
median (range) 8 (1-17) vs 12.5 (1-53); p=0.04 and less time spent below 63mg/dl 
(1.6 vs 2.7%; CI95% -0.2 to -2.1; p=0.02). Time below 50mg/dL (0.24 vs 0.47%; 
CI95% -0.02 to -0.5; p=0.03) and low blood glucose index (1.0 vs 1.4; CI95% -0.7 to -
0.1; p=0.01) were lower during closed-loop. 
There was less overnight time (23.00-07.00h) below 63mg/dl during closed-loop 
(1.1 vs 2.7%; CI95%  -2.8 to -0.4; p=0.008). The overnight time-in-target was also 
higher during closed-loop but this difference did not reach statistical significance 
(67.7 vs 60.6%; CI95%  -0.8 to 15.2; p=0.06; Supplemental Table S1 ) .  
There were no episodes of severe hypoglycemia. The mean (SD) HbA1c was 6.6% 
(2.8) (48.5mmol/mol [7.5]), 6.4% (2.7) (46.3mmol/mol [5.6]) and 6.3% (2.7) 
(45.9mmol/mol [5.5]), at baseline, end of closed-loop and end of SAP, respectively. 
There was no difference in HbA1c between baseline and the end of each phase 
(p=0.15 and p= 0.14 for closed-loop and SAP respectively), and no difference in 
HbA1c during closed-loop and SAP (p=0.67). There were no differences in total 
insulin doses, although basal insulin delivery was, as expected, more variable during 
closed-loop (SD 0.1 vs 0.8; p<0.0001; Supplemental Table S2).  
The quality and quantity of sleep were comparable, with a sleep duration of 7.5 (0.8) 
during closed-loop and 7.1 (1.2) hours during SAP (p=0.22). There were no 
differences in the patient-reported questionnaires. Most participants (>80% at the end 
of both phases) reported less fear of nocturnal hypoglycemia, although over a third 
experienced ongoing worry or fear about low blood sugars during sleep.  
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There were no reportable serious adverse events but there were frequent device 
deficiencies, most frequently, involving the closed-loop mobile phone (47%) and 
CGM (30%) devices with fewer concerns regarding the insulin pump (13%) and 
device downloads (10%; Supplemental Table S3).  
Longer-term antenatal feasibility  
All women chose to continue using closed-loop, for at least some of the time, after 
the randomized trial, with median time-in-target of 70.6% (16.9 hours/day) between 
28-32 weeks gestation, 71.5% (17.2 hours/day) 32-36 weeks, and 72.3% (17.4 
hours/day) from 36 weeks until delivery (Figure 2, Table 3). One participant travelled 
to the Middle East (participant 8), for 8 weeks without contact or antenatal care. 
Another relocated to Australia, and continued closed-loop until delivery (participant 
15). Details of individual participant’s glucose control are shown (Figure 2). 
Post-partum closed-loop feasibility 
After delivery, 12 women chose to continue using closed-loop. They maintained safe 
glucose control, with 77.1% time-in-target (70-180mg/dl) and minimal 
hypoglycemia (2.3% < 70mg/dl) during the first 6-weeks post-partum (Table 3). 
Sensor wear was variable after delivery, with a median of 16.5 hours/day. Where 
post-partum sensor wear was low, it was generally the case that the participant used 
CGM for the lifespan of a sensor, with gaps between the expiry of one sensor and 
insertion of a new one (Supplemental Table S4).  
Obstetric and neonatal outcomes 
Participants delivered at a median (interquartile range) gestation of 36.9 (36.1 - 37.8) 
weeks gestation. Thirteen were delivered by caesarean section, seven of which 
14 
 
occurred prior to the onset of labor. Two participants developed pre-eclampsia. One 
participant had a placental abruption. The median (interquartile range) neonatal 
birthweight was 3575g (3073-3745). Seven (44%) were LGA ≥90th centile, with five 
≥ 97th centile. One neonate, born to a mother with excellent glucose control 
(participant 7), was small-for-gestational age (birthweight 2880g), but was healthy 
and without complications. Eleven (69%) infants were admitted to NICU, with seven 
(44%) treated for hypoglycemia (Supplemental Table S5, S6).  
Two infants had congenital anomalies. One had a neural tube defect (lumbar/sacral 
lipomyelomeningocele) detected post-partum. This mother had an unplanned 
pregnancy (booking HbA1c 8.1%), switched from MDI to closed-loop with good 
effect and maintained excellent glucose control throughout pregnancy (participant 2). 
Another infant had severe unilateral hydronephrosis (10mm renal pelviceal dilatation 
detected at 20 weeks gestation). This participant (booking HbA1c 9.7%), conceived 
spontaneously after four unsuccessful cycles of IVF, also switched from MDI to 
closed-loop, with a striking fall in HbA1c (5.0%) despite modest time-in-target (56%) 
in late pregnancy (Supplemental Table S5, S6).  
Inter-individual variability 
The individual participant data highlights variability in women’s glycemic responses 
to closed-loop (Figure 2). This does not appear related to previous technology use as 
glycemic control was comparable in participants who used CSII or MDI at enrolment 
(Supplemental Table S7). Five participants (31%) spent less time in target and had 
higher mean glucose levels during closed-loop. These included two CSII (participants 
3, 5) and three MDI users (participants 4, 6, 13) had ≥10% lower time-in-target during 
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the closed-loop crossover, although they all continued to use closed-loop, with higher 
time-in-target, in later pregnancy. 
Post hoc analyses suggested that participants with lower booking HbA1c levels 
(≤7.5%) had higher time-in-target both during closed-loop and SAP phases, 
compared to those with HbA1c>7.5% (Table 4). This pattern persisted throughout 
pregnancy, including after 36 weeks, when participants with lower HbA1c in early 
pregnancy maintained excellent glucose control (mean glucose 115mg/dl, 78% 
equivalent to 18.7 hours/day in-target). Participants with suboptimal glucose control 
in early pregnancy had higher mean glucose and lower time-in-target, even after 36 
weeks gestation, (126mg/dl, 69% in-target or 16.6 hours/day).  
Discussion 
We found that day-and-night closed-loop was safe, and could effectively control 
glucose levels in a broad range of pregnant women with T1D. Participants achieved 
comparable glucose control during SAP and closed-loop, with no between-group 
differences in time-in-target, mean glucose, or HbA1c levels. There was a reduction 
in frequency of maternal hypoglycemic events and reduced exposure both to overall 
and to nocturnal hypoglycemia during closed-loop.  
The current study is part of a phased programme of developing and evaluating closed-
loop in pregnancy. The first non-randomized, proof of concept study (n=10 
participants) demonstrated the ability of closed-loop to adjust overnight insulin 
delivery in early and late gestation in a closely supervised clinical research facility 
setting (21). The second study (n=12 participants) compared day-and-night closed-
loop with SAP, over 24 hours in the clinical research facility (16). The third was the 
first home study of overnight closed-loop with the same sample size (n=16), 
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randomized crossover design, same SAP comparator and duration of intervention as 
the current study (14). The stepwise progression from clinical research facility to 
home and from overnight to day-and-night is necessary to document initial safety and 
feasibility before proceeding with a pivotal clinical trial. 
A recent systematic review found that outside of pregnancy, closed-loop was 
associated with a 12.6% increased time-in-target range where the comparator (SAP 
in 21/22 single hormone closed-loop studies), spent 58% time (13.3 hours/day) in the 
wider glucose target range of 70-180mg/dl (11). In the current study, where both 
groups had over 60% time-in-target range (63-140mg/dl for T1D pregnancy), no 
further improvement was obtained. Our previous study of overnight closed-loop in 
pregnancy (14), also found that compared to SAP, closed-loop was associated with a 
15% higher time-in target (75 vs 60%; p<0.002). In our current study, women using 
SAP achieved comparable overnight glucose control, but the impact of closed-loop 
effect was less, with a 7% non-significant increase (68 vs 61%; p=0.06).  
There are several potential explanations for our findings. Firstly, the level of glucose 
control achieved with SAP (60% in 70-140mg/dl, and 82.5% in 70-180mg/dl range), 
in pregnancy is considerably higher than in previous studies outside pregnancy (8, 9, 
11). The glucose control achieved with SAP in our study was comparable or higher 
than that achieved with closed-loop previously (8, 9), including in well-controlled 
adults (HbA1c <7.5%), thereby minimising the potential for further improvement 
(10). The role of closed-loop, in well-controlled adults, may be to reduce the burden 
of hypoglycemia without deterioration in glucose control.  
Secondly, the small sample size of this phase 2a study, meant that we lacked 
statistical power for anything other than the power calculation assumption of a 30% 
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between-group difference. Recent results from a CGM trial in 215 T1D pregnancies 
suggest that even small differences, a 7% increase time-in-target and 5% reduction 
in hyperglycemia in CONCEPTT, are associated with substantial (approximately 
50%) reductions in neonatal complications (5). The current study was underpowered 
to detect small differences.   
Thirdly, we consciously enrolled a broad patient population for this study, including 
women with variable levels of technology experience, diabetes education and 
glycemic control. The majority were technology naïve with over 80% sensor naïve 
and 50% pump naïve at enrolment. Over half had suboptimal booking HbA1c levels, 
defined as HbA1c>7.5% at the first antenatal visit. Among the five women with lower 
time-in-target during closed-loop, one cycled 30-60mins twice daily and struggled to 
avoid post-exercise hypoglycemia (participant 3), while another who worked as an 
events planner, had more night shifts during closed-loop (participant 4). Three 
women (participants 4, 6, 13) were frequent non-attenders at antenatal clinics and had 
minimal contact with the research team. All three used closed-loop to good effect in 
late gestation.  
The influence of lifestyle and behavioural factors during closed-loop is not well 
understood. Recent data suggest that behavioural factors, including snacking, account 
for approximately one third of the intra-individual variability in glucose levels during 
closed-loop (22). The frequency of pre-meal bolusing is also important, emphasising 
the need for ongoing diabetes education and support with closed-loop (23). Others 
have commented that closed-loop may have unintended impacts on dietary intake, 
and proposed that education to optimise healthy eating patterns be incorporated into 
closed-loop training (24). 
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Previous qualitative research suggests that some participants may have unrealistic 
expectations placing too much trust in closed-loop (15). This was echoed by pre-trial 
comments from current participants; “The way I see it is literally this app on this 
phone is literally going to take my brain away basically, which is happy days” 
(participant 4). During the qualitative interview, she commented that her motivation 
to participate, was partly to avoid finger-stick testing; “I’m not the best with blood 
tests but that’s because I kind of more or less listen to the symptoms of highs and 
lows rather than doing a test, which is naughty, but that’s the reason I wanted to go 
on the CLIP”. Other authors have reported that the current “closed-loop/artificial 
pancreas” terminology, may imply a more "hands-off" approach (25).   
While sensor use was reasonable for this patient population (approximately 20 of 24 
hours), use of closed-loop was affected by technical problems that frequently 
required closed-loop to be reset. The algorithm is adaptive, meaning that its 
performance improves for an individual over time. System errors requiring that the 
system be reset meant that the algorithm returned to participant-naïve parameters. 
Technical issues may have reduced womens trust, which may also have contributed 
to them being tempted to override the algorithm advice (26).  
After 28 weeks gestation, women achieved good overall glycemic control (71-73% 
time-in-target). This is comparable to our overnight home closed-loop study, in well-
controlled women (baseline HbA1c 6.6%), who achieved 68-71% time-in-target (14). 
It is 10% higher than the control group in CONCEPTT (61% time-in-target) but 
comparable to the CONCEPTT CGM group (68% time-in-target) (5). The 
CONCEPTT participants had lower baseline HbA1c levels and substantially more 
hypoglycemia with 4% time <63.0 mg/dl and 3.5 hypoglycemia episodes/week. 
Taken together these data suggest that closed-loop facilitates good day-to-day 
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glucose control in a broad patient population, and is effective for minimising risk of 
hypoglycemia. There were no episodes of severe hypoglycemia during the current or 
previous closed-loop trials. We also found that despite frequent device hassles, 75% 
of women continued closed-loop after delivery, and for up to 6-weeks post-partum.  
We cannot directly compare these pregnancy outcomes to the publicly reported data 
for all pregnancies from these sites (https://digital.nhs.uk/catalogue/PUB30109), 
since the women in this study were three years older and had a five year longer 
duration of diabetes (19.4 vs 14.0 years). Larger trials of longer duration closed-loop 
are be needed to understand the effect on maternal glucose control and infant health 
outcomes in routine care settings.  
Meanwhile it is clear that the obstetric and neonatal outcomes in T1D pregnancy 
remain suboptimal, suggesting that while the burden of maternal hypoglycemia can 
be minimised, excessive fetal exposure to maternal hyperglycemia persists. More 
research is needed to address the potentially modifiable dietary and snacking 
behaviours that contribute to post-prandial hyperglycemia and are still challenging 
during closed-loop.  
Strengths of this study include the randomized crossover design, eliminating inter-
individual variability in insulin sensitivity, dietary intake, and exercise patterns and 
reducing the impact of gestation or the order of interventions. The analyses were 
performed as intention to treat regardless of compliance. Participants were recruited 
from three NHS sites, including women without diabetes technology experience and 
with a wide range of glucose control. We did not use remote monitoring or restrict 




We also acknowledge the limitations. The crossover design may not have been 
suitable for participants with variable lifestyles (e.g., night workers, overseas travel). 
The relatively short 4-week duration may have been insufficient for optimal closed-
loop training particularly for device naïve participants and those with less advanced 
self-management skills. While the prototype closed-loop system was portable and 
generally well received, it had frequent errors. This frustrated participants, and 
reduced the time that closed-loop was operational. The SAP control group did not 
have the option of suspending insulin delivery during low or predicted low glucose 
level.  
In this cohort of pregnant women with type 1 diabetes, with a broad range of glucose 
control, closed-loop was as effective as SAP therapy, but potentially safer, because 
closed-loop reduced the extent and duration of hypoglycemia. More research is 
needed to improve glucose control in postprandial times and to develop closed-loop 
training programmes to support optimal self-management behaviours, particularly 
for women who enter pregnancy with higher HbA1c. Larger trials of longer duration 
closed-loop are required to determine proof of clinical efficacy of in pregnancy and 
to establish whether future closed-loop systems may help to minimise neonatal 
complications in T1D pregnancy.   
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Figure Legends:  
Figure 1: Consort Flow Diagram  
Figure 2: Glycemic control during the randomized crossover trial and antenatal 
closed-loop feasibility phase by individual participant  
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Table 1: Baseline characteristics of trial participants  
Baseline characteristics (N=16) Number (%) Mean (SD) 
Age (years)  32.8 (5.0) 
BMI (kg/m2)  26.6 (4.4) 
Booking HbA1c† (%)  8.0 (1.1) 
Booking HbA1c (mmol/mol)  63.7 (12.1) 
Booking HbA1c >7.5% (58mmol/mol) 9 (56%)  
Duration of diabetes (years)  19.4 (10.2) 
Insulin pump use prior to study 8 (50) 
 
CGM use prior to study± 3 (19)  
Total daily insulin dose (units/kg/day)  0.51 (0.09) 
Weeks gestation*  16.4 (4.9) 
Primiparous‡ 6 (38) 
 
Recruitment site   
Cambridge 6 (38)  
Norwich 8 (50)  
Ipswich 2 (12)  
†The booking HbA1c is the measurement taken at the first antenatal clinic visit following 
confirmed pregnancy  
* Weeks gestation at randomization. Randomization was performed after recruitment and at 
least 2 to 4 weeks of device training when insulin regimens were optimised and participants 
were competent using the study pump and CGM devices. 
± None of the 3 participants had used CGM in the 6 months prior to enrollment in the study 
or as part of their regular diabetes management. Two had used real-time CGM 
(C24_03_06, C24_01_12) and one Freestyle Libre (C24_02_15). 
‡6 participants had experienced previous pregnancy losses (6 miscarriages and 1 stillbirth), 
2 women had had termination of pregnancy for major malformation. 2 women had a history 













Time in T1D pregnancy target 
range (%)* 
60.1 62.3 2.1 (-4.1 to 8.3) 0.47 
Secondary glycemic outcomes 
Mean CGM glucose (mg/dl)                                                       131.4 131.4 0 (-0.3 to 0.4) 0.85 
Time > 140mg/dl or 7.8mmol/L (%) 36.6 36.1 -0.6 (-7.4 to 6.3) 0.86 
Time >180mg/dl or 10mmol/L (%) 14.8 14.6 -0.1 (-4.2 to 4.0).  0.94 
Time <63mg/dl or 3.5mmol/L (%) 2.7 1.6 -1.1 (-0.2 to -2.1) 0.02 
Time 50mg/dl or < 2.8mmol/L (%) 0.5 0.2 -0.2 (-0.0 to -0.5) 0.03 
Number of hypoglycemic events 
over 28 days 
12.5 (1-53) 8 (1-17)  0.04 
Low blood glucose index (LGBI) ± 1.4 1.0 -0.4 (-0.7 to -0.1) 0.01 
Standard deviation of sensor glucose 
(mg/dl) 
37.8 36.0 -12.6 (-3.6 to 1.8) 0.29 
TDD insulin (units/day) 41.5 43.7 2.2 (-6.4 to 0.7) 0.56 
Sensor wear (hours/day) 20.3 20.2   
The values reported are derived from linear mixed effects models except for number of 
hypoglycemic events which are median (range) and defined as sensor glucose values 
<63mg/dl for ≥20 minutes. 
* The primary efficacy endpoint was the percentage of time that glucose was in the T1D 
pregnancy target range of 63-140mg/dl (3.5-7.8mmol/L), as recorded by CGM during each 
4-week study phase.  




Table 3: Glycemic control during the antenatal and post-partum closed-loop 
feasibility phases±.  
 Antenatal feasibility Postnatal 
feasibility 
 28-32 weeks 32-36 weeks >36 weeks 0-6 weeks 
 n=8 n=16 n=9 n=12 


















% time below 
target range 



















N/A 16.5 (11.6, 
19.2) 
Data are median (interquartile range) 
±The antenatal closed-loop feasibility phase was from the end of the randomized crossover 
trial until delivery. The postnatal closed-loop feasibility phase was from delivery up to 6 
weeks post-partum.  
*The glucose target range was 63-140mg/dl (3.5-7.8mmol/L) during pregnancy and 70-




Table 4:Glycemic control during the randomized crossover trial and antenatal closed-loop feasibility phase in participants with HbA1c 
levels≤7.5% or >7.5% (58mmol/mol) at their first antenatal clinic visit. 
 
†The booking HbA1c is the measurement taken at the first antenatal clinic visit following confirmed pregnancy  
*Indicates significant difference between participants with HbA1c ≤7.5% compared with booking HbA1c >7.5% (p<0.05) 



























% Time in target 
(63-140mg/dl)  
69.1* 72.1* 3 72.0 74.0 77.7* 57.0* 57.3* 0.3 64.6 69.0 68.8* 
% Time below 
63mg/dl 
1.0 0 -1.0 1.6 2.7 4.1* 0 0.2 0.2 3.0 2.6 1.5* 
Mean glucose 
(mg/dl) 
122.4* 120.6* -1.8 122.4 117.0 115.2* 136.8* 142.2* 5.4 127.8 124.2 126.0* 
